Heartflow, Inc.
Heartflow provides cloud-based software and artificial intelligence for physicians diagnosing and managing coronary artery disease. Its Heartflow Platform analyzes a patient’s coronary CT angiography scan and creates a personalized 3D model with information about blood flow, narrowing, plaque volume and plaque composition. The platform’s products include Heartflow RoadMap Analysis, which supports image review; Heartflow FFRCT Analysis, which assesses blood flow and clinically significant disease; and Heartflow Plaque Analysis, which measures and characterizes plaque. Heartflow PCI Navigator is described as a planned product. Heartflow primarily makes money by charging accounts each time a physician selects Heartflow FFRCT Analysis, Heartflow Plaque Analysis or both for review. RoadMap Analysis is generally provided as an integrated workflow feature rather than a stand-alone product. The platform is used by hospitals and outpatient imaging facilities, and Heartflow has an installed base of more than 1,465 accounts in the United States as of December 31, 2025. Heartflow is headquartered in San Francisco, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wells Fargo raised its price target for HeartFlow to $70 from $39, citing a 16.8% upside from the Nov 12 close. The firm maintained an Overweight rating. Recent analyst targets range from $64 to $70.
Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.
Baird reaffirmed its Outperform rating for HeartFlow and increased its price target to $68 from $56, suggesting a 13.5% upside from the Nov 12 close of $59.92, according to the firm.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning HTFL (Heartflow, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 2 bearish.
Recent HTFL coverage spans financial news, earnings and insider activity.
In the last 30 days, HTFL insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.7M). The most active reporter was Verghese Vikram, Chief Financial Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Wells Fargo raised its price target for HeartFlow to $70 from $39, citing a 16.8% upside from the Nov 12 close. The firm maintained an Overweight rating. Recent analyst targets range from $64 to $70.
Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.
Baird reaffirmed its Outperform rating for HeartFlow and increased its price target to $68 from $56, suggesting a 13.5% upside from the Nov 12 close of $59.92, according to the firm.
Analyst upgrade and higher guidance suggest further upside.
The earnings beat on loss but guidance raise was insufficient, leading to a modest sell‑off.
AlphAI scores every news story that mentions HTFL with an AI model for sentiment and relevance, and aggregates insider trades from Heartflow, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo raised its price target for HeartFlow to $70 from $39, citing a 16.8% upside from the Nov 12 close. The firm maintained an Overweight rating. Recent analyst targets range from $64 to $70.
Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.
Baird reaffirmed its Outperform rating for HeartFlow and increased its price target to $68 from $56, suggesting a 13.5% upside from the Nov 12 close of $59.92, according to the firm.
Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.
Heartflow (HTFL) reported Q3 revenue of $72.9M, up 57% YoY, and adjusted loss per share of -$0.03, beating estimates. The company raised 2026 revenue guidance to $262M-$264M. Shares fell 5% post-earnings.
Heartflow, Inc. (HTFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heartflow Reports Third Quarter 202 6 Financial Results and Raises Full Year 2026 Guidance SAN FRANCISCO — November 1 2 , 202 6 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today
Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $55.74 ($2.17M total) on 2026-11-10 under a Rule 10b5-1 trading plan.
Heartflow, Inc. (HTFL) presented data at TCT 2026 showing its CT-guided PCI planning matched IVUS outcomes with 17-minute shorter procedures and 12% less contrast in a 1,105-patient trial. NAVIGATE-PCI registry showed 70% of treatment plans modified using Heartflow PCI Navigator. BRAVEHEART registry found 72% of firefighters had subclinical plaque.
Rogers Campbell (Chief Medical Officer) sold 23,933 shares of Heartflow, Inc. (HTFL) at $55.01 ($1.32M total) on 2026-10-22 under a Rule 10b5-1 trading plan.
Piper Sandler maintained an Overweight rating on HeartFlow with a $64 price target, suggesting a 25.4% upside from the Oct 19 close. The firm cited HeartFlow's strong market position, growth potential, and durable competitive moat in non-invasive coronary artery disease detection.
